3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
9
Thoracic
5
Genitourinary
3
Dermatologic
3
Sarcoma
2
Head & Neck
2
Breast
2
Other solid neoplasm
1
Lymphoid
1
Gynecologic
1
Conditions
Lymphoma
11
Lymphoma, Non-Hodgkin
10
Multiple Myeloma
9
Leukemia, Lymphocytic, Chronic, B-Cell
9
Hodgkin Disease
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Neoplasms
6
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma, Follicular
5
Hematologic Neoplasms
5
Burkitt Lymphoma
5
Neuroblastoma
4
Lymphoma, Mantle-Cell
4
Lymphoma, Large-Cell, Immunoblastic
4
Lymphoma, B-Cell, Marginal Zone
4
Lymphoma, B-Cell
4
Leukemia, Myeloid, Acute
4
Breast Neoplasms
4
Neoplasm Metastasis
3
Myelodysplastic Syndromes
3
Melanoma
3
Lymphoma, T-Cell, Cutaneous
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Waldenstrom Macroglobulinemia
2
Sarcoma
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Myeloproliferative Disorders
2
Mycosis Fungoides
2
Lymphoma, T-Cell
2
Interventions
pembrolizumab
3
Sirolimus
2
Drug Therapy
2
Carboplatin
2
Blood Specimen Collection
2
spartalizumab
1
ixabepilone
1
fludarabine
1
etoposide phosphate
1
durvalumab
1
atezolizumab
1
advexin
1
Topotecan
1
Tissue Banks
1
Thiotepa
1
Radiotherapy
1
Quality of Life
1
Psychology, Positive
1
Psychiatric Rehabilitation
1
Patient Reported Outcome Measures
1
Observation
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Microarray Analysis
1
Methods
1
Leucovorin
1
Ipilimumab
1
Interleukin-2
1
Immunotherapy
1
Immunohistochemistry
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liver Neoplasms
×
Ipilimumab
×
Lymphoid
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts